{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-23-000003","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.828507+00:00","generated_at":"2026-06-19T07:00:18.204845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medtronic Q3 FY2023 revenue $7.73B (+4.1% organic), non-GAAP EPS $1.30, raises FY guidance","bullets":["Revenue $7.727B flat as reported, +4.1% organic; GAAP EPS $0.92 (-16%), non-GAAP EPS $1.30 (-4%), both ahead of expectations.","Cardiovascular +7% organic, Neuroscience +7% organic; Medical Surgical -2% organic (ex-ventilator/China +3%).","FY2023 non-GAAP EPS guidance raised to $5.28-$5.30 from $5.25-$5.30; Q4 organic revenue growth expected 4.5-5.0%.","Planned separations: Respiratory/Patient Monitoring (H2 FY2024) and Renal Care Solutions with DaVita (Q4 FY2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-23-000003","json":"https://secwatch.observer/filing/0001613103-23-000003.json","markdown":"https://secwatch.observer/filing/0001613103-23-000003.md","text":"https://secwatch.observer/filing/0001613103-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/0001613103-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/mdt-20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:00:18.204845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0e17e098c1c1fd2e725bf89c0becdcf206811ac","claim":"Medtronic plc reported third quarter fiscal year 2023 ended January 27, 2023 results: revenue $7.727 billion, net income $1.222 billion (GAAP); $1.727 billion (non-GAAP), EPS $0.92 (GAAP diluted); $1.30 (non-GAAP diluted). Guidance raised.","evidence_excerpt":"Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN – Feb. 21, 2023 – Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights • Revenue of $7.7 billion was flat as reported and increased 4.1% organic, ahead of expectations • GAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectations • Company increases FY23 organic revenue growth and EPS outlook","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310323000003/0001613103-23-000003-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter fiscal year 2023 ended January 27, 2023"},{"label":"Revenue","value":"$7.727 billion"},{"label":"Net income","value":"$1.222 billion (GAAP); $1.727 billion (non-GAAP)"},{"label":"EPS","value":"$0.92 (GAAP diluted); $1.30 (non-GAAP diluted)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}